Astellas Pharma

Diversified pharma

4503 · TSE · Japan

Public Market Listing

4503TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Astellas Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(15 total)
15Total Assets
4Approved
4Phase 3 / Filed
7Phase 1–2 / Early
14Diseases
Quick filter:
Showing 15 of 15 assets
Target & Modality
Approved
Complement C5Other
Age-Related Macular Degeneration
Approved
Nectin-4Antibody–drug conjugate
Non-Small Cell Lung CancerBladder Cancer
Approved
FLT3Small molecule
Non-Small Cell Lung CancerAcute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
linaclotide(Linzess)
Approved
Guanylate cyclase-C (GC-C)Peptide
Irritable Bowel Syndrome
Irritable Bowel Syndrome with Constipation
Phase 3
Claudin 18.2 x CD3Multispecific antibody
Gastric Cancer
Bixalomer(Kiklin)No recent activity
Phase 3
Phosphate binderSmall molecule
Chronic Kidney DiseaseHyperphosphatemia
Roxadustat(Evrenzo)
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney DiseaseMyelodysplastic Syndromes
Phase 3
KRAS G12DSmall molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Phase 2
CYP17 lyaseSmall molecule
Prostate Cancer
Phase 1/2
MTM1 (myotubularin)Gene therapy / editing
X-Linked Myotubular Myopathy
Phase 1/2
Claudin 18.2 (CLDN18.2)Antibody–drug conjugate
Non-Small Cell Lung CancerGastric Cancer
Phase 1/2
GAA (acid alpha-glucosidase)Gene therapy / editing
Pompe Disease
Phase 1
Pan-KRASSmall molecule
Non-Small Cell Lung Cancer
Phase 1
—Cell therapy
Geographic Atrophy
Phase 1
PSMA x CD3Multispecific antibody
Prostate Cancer

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ASP546CPhase 1/2Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic, Biliary Tract Cancer …
Est. primary completion 2026-12-30 · NCT06792435 · CT.gov ↗
What to watch
2027 (4)
October 2027 (2)
Roxadustat · EvrenzoPhase 3Chronic Kidney Disease, Renal Anemia
Est. primary completion 2027-10-30 · NCT05970172 · CT.gov ↗
What to watch
ASP2957Phase 1/2X-Linked Myotubular Myopathy
Est. primary completion 2027-10-31 · NCT07052929 · CT.gov ↗
What to watch
November 2027 (1)
Enfortumab VedotinPhase 2Muscle-invasive Bladder Cancer
Est. primary completion 2027-11-30 · NCT07475806 · CT.gov ↗
What to watch
December 2027 (1)
Enfortumab VedotinPhase 1/2Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Est. primary completion 2027-12-28 · NCT07421700 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
GilteritinibPhase 1/2Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
Est. primary completion 2028-07-31 · NCT05520567 · CT.gov ↗
What to watch
2029 (3)
June 2029 (1)
Enfortumab VedotinPhase 1/2Locally Advanced or Metastatic Malignant Solid Tumors
Est. primary completion 2029-06-30 · NCT07287995 · CT.gov ↗
What to watch
July 2029 (1)
ASP546CPhase 1/2Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Est. primary completion 2029-07-31 · NCT07488676 · CT.gov ↗
What to watch
August 2029 (1)
SetidegrasibPhase 3Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Est. primary completion 2029-08-31 · NCT07409272 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
Enfortumab VedotinPhase 3Urothelial Cancer, Urinary Bladder Neoplasms
Est. primary completion 2030-03-31 · NCT07566156 · CT.gov ↗
What to watch
June 2030 (1)
SetidegrasibPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2030-06-30 · NCT07566052 · CT.gov ↗
What to watch
September 2030 (1)
Roxadustat · EvrenzoPhase 3Myelodysplastic Syndromes
Est. primary completion 2030-09 · NCT07722988 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
ASP2138Phase 3Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Est. primary completion 2031-02-28 · NCT07673887 · CT.gov ↗
What to watch
2032 (2)
May 2032 (1)
Abiraterone decanoatePhase 2Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Est. primary completion 2032-05-31 · NCT07005154 · CT.gov ↗
What to watch
July 2032 (1)
ASP2957Phase 1/2X-linked Myotubular Myopathy
Est. primary completion 2032-07-31 · NCT07876804 · CT.gov ↗
What to watch
2035 (1)
February 2035 (1)
Zocaglusagene nuzaparvovecPhase 1/2Pompe Disease (Late-onset)
Est. primary completion 2035-02-28 · NCT04174105 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(18)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026ApprovalEnfortumab VedotinEuropean Commission expands Padcev approval to resectable MIBC
EU, EC · Source ↗
17 August 2026FDA action dateEnfortumab VedotinPDUFA target action date August 17, 2026
US, FDA · Source ↗
7 July 2026Filing acceptedEnfortumab VedotinNMPA accepts BLA for Padcev plus Keytruda in muscle-invasive bladder cancer
CN, NMPA · Source ↗
20 April 2026Filing acceptedEnfortumab VedotinFDA accepts sBLA for perioperative PADCEV + Keytruda in MIBC
US, FDA · Source ↗
20 April 2026Priority reviewEnfortumab VedotinFDA grants Priority Review to PADCEV + Keytruda sBLA in MIBC
US, FDA · Source ↗
7 April 2026FDA action dateEnfortumab VedotinPDUFA target action date set for April 7, 2026
US, FDA · Source ↗
9 March 2026Topline resultGilteritinib (Xospata)Phase 3 HOVON 156 / AMLSG 28-18 / PASHA (NCT04027309) missed its overall survival primary endpoint
Astellas Pharma Inc. and HOVON · Source ↗
17 December 2025Topline resultEnfortumab VedotinEV-304 Phase 3 interim topline results positive
22 October 2025Filing acceptedEnfortumab VedotinFDA accepts the PADCEV plus KEYTRUDA sBLA in MIBC and grants Priority Review
US, FDA · Astellas Pharma · Source ↗
18 October 2025Topline resultEnfortumab VedotinEV-303 Phase 3 positive topline results for PADCEV plus KEYTRUDA in MIBC
26 February 2025FDA action dateAvacincaptad pegolTarget action date set for IZERVAY sNDA
US, FDA · Source ↗
12 February 2025ApprovalAvacincaptad pegolFDA approves expanded IZERVAY label without limit on dosing duration
US, FDA · Source ↗

The 12 most recent of 18 past events are shown.

Financial reports

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$14.1B$2.1B$1.8B—report ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$12.6B$2.2B$1.3B—report ↗
2024-FY$11.0B$2.0B$2.2B—report ↗
2023-FY$11.2B$2.0B$2.8B—report ↗
2022-FY$11.5B$2.2B$2.6B—report ↗
2021-FY$11.8B$2.1B$3.0B—report ↗